Key facts
- Notable investors include DFW Capital Partners, Pelham S2K.
- Status: Acquired/Merged (Operating Subsidiary).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Voiant
- ·The full record, as it builds
Funding rounds
No funding rounds for Voiant are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Voiant
Operator of a contract research organization intended to serve biopharmaceutical and medical device organizations. The company provides image consulting, acquisition, assessment, management, reporting and archiving services for pharmaceutical and medical device clinical trials, thereby offering sponsors extensive medical, operational and image management expertise in support of complex study designs.
- Sector
- Business Products and Services (B2B)
- HQ
- Boston, MA, United States
- Founded
- 1992
- Employees
- 125
- Website
- voiantclinical.com/
- Ownership
- Acquired/Merged (Operating Subsidiary)
Voiant doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Voiant shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Voiant in its N-PORT filings yet. We sweep new filings monthly.